UNIFIED Unifying Framework for Patient-centred Clinical-study Endpoints derived from Digital Health Technologies
- Coordinator
- Erasmus Universiteit Rotterdam, Netherlands
- Runs
- 1 November 2025 to 31 October 2030
- Status
- Running
- EU funding
- €12.6m
- Total cost
- €23.0m
- Partners
- 51 organisations in 17 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101218845
What the project is doing
In the project's own words, from its summary on CORDIS.
Motivation: Failing to incorporate patient perspectives in healthcare decisions leads to sub-optimal care. Despite increasing emphasis from industry and policy-makers this is not yet common practice. Main objectives: UNIFIED is a public-private partnership involving universities, industry, patient groups, medical centres, HTA bodies, and clinical guideline organisations. It is designed to generate a UNIFIED Framework for obtaining a robust view of a health intervention’s full benefits to patients via (i) integrating three key data types: patient preference information, clinical outcome assessments, and digital health technology (DHT)-derived measures, and (ii) determining what patients consider minimum clinically important difference.
Leveraging cutting-edge AI, particularly Foundation Models, UNIFIED integrates these diverse patient-centred data types reliably, while employing advanced safeguards. UNIFIED uses a structured, interactive, and multimethod approach, fostering synergy between academic expertise and fast experience in pharmaceutical and MedTech industry. Validation of the initial framework will occur through well-aligned complementary use cases in five medical domains across Europe and Canada and an adoption approach for patients, caregivers, clinicians, industry, regulatory/HTA/reimbursement bodies.
Main deliverables: A robust evidence- and consensus-based UNIFIED Framework with recommendations for integrating patient-centred clinical-study endpoints. The framework will provide clear, actionable guidance for timely and effective use of patient-centred, DHT-derived data as clinical endpoints. Expected long-term impact: Through its evidence- and consensus-based framework and recommendations, UNIFIED empowers patients, caregivers, clinicians, industry, regulatory/HTA/reimbursement bodies to make patient-centred healthcare decisions.
This will drive measurable improvements across the healthcare ecosystem, benefitting patients, caregivers, clinicians, industry, regulatory/HTA/reimbursement bodies, and society. Ultimately, UNIFIED will enhance patient-centred care by ensuring healthcare decisions reflect true value to patients, thus improving patient outcomes, while ensuring healthcare’s long-term effectiveness and economic sustainability.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Erasmus Universiteit Rotterdam | Rotterdam | Netherlands | Coordinator |
| European Academy of Neurology | Wien | Austria | Participant |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Amgen | Diegem | Belgium | Participant |
| Association Europeenne Pour La Maladie De Parkinson | Bruxelles / Brussel | Belgium | Participant |
| Forum Des Patients Europeens | Bruxelles / Brussel | Belgium | Participant |
| Iqvia Solutions Belgium | Zaventem | Belgium | Participant |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Ucb Biopharma | Bruxelles / Brussel | Belgium | Participant |
| 9197-1168 Quebec in | Montreal | Canada | Participant |
| Cassie and Friends: A Society for Children with Juvenile Arthritis and other Rheumatic Diseases | Vancouver | Canada | Participant |
| The Hospital for Sick Children | Toronto | Canada | Participant |
| University of Calgary | Calgary Alberta | Canada | Participant |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Novartis Pharma AG | Basel | Switzerland | Participant |
| Collaborate Project Management GmbH | Munchen | Germany | Participant |
| Hochschule Neubrandenburg | Neubrandenburg | Germany | Participant |
| Pfizer Pharma GmbH | Berlin | Germany | Associatedpartner |
| Siemens Healthineers AG | Forchheim | Germany | Participant |
| H2o Pan European Observatory | Nordhavn | Denmark | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Fundacion Publica Andaluza Progreso Y Salud M.p. | Sevilla | Spain | Participant |
| Hus-Yhtyma | Helsinki | Finland | Participant |
| Pfizer International Operations | Paris | France | Associatedpartner |
| The European Coalition for People Living with Obesity Company Limited by Guarantee | Dublin | Ireland | Participant |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs | Roma | Italy | Participant |
| Istituto Europeo Di Oncologia SRL | Milano | Italy | Participant |
| Universita Degli Studi Di Milano | Milano | Italy | Participant |
| Childhood Cancer International | Amsterdam | Netherlands | Participant |
| Janssen Biologics BV | Leiden | Netherlands | Participant |
| Pancare | Bussum | Netherlands | Participant |
| Prinses Maxima Centrum Voor Kinderoncologie BV | Utrecht | Netherlands | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Universiteit Twente | Enschede | Netherlands | Participant |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Participant |
| Uniwersytet Jagiellonski | Krakow | Poland | Participant |
| Promptly - Software Solutions for Health Measures SA | Trofa | Portugal | Participant |
| Astrazeneca AB | Sodertaelje | Sweden | Participant |
| Evinova AB | Mölndal | Sweden | Associatedpartner |
| Molnlycke Health Care AB | Goteborg | Sweden | Participant |
| Iqvia Ltd | Reading | United Kingdom | Associatedpartner |
| Janssen Cilag Limited | High Wycombe | United Kingdom | Associatedpartner |
| Pfizer Limited | Sandwich | United Kingdom | Associatedpartner |
| Pfizer R&D UK Limited | Sandwich | United Kingdom | Associatedpartner |
| Abbvie Inc | North Chicago Il | United States | Participant |
| Amgen Inc | Newbury Park | United States | Associatedpartner |
| AstraZeneca Pharmaceuticals LP | Wilmington | United States | Associatedpartner |
| Janssen Research & Development, LLC | Raritan | United States | Associatedpartner |
| John Snow Labs Inc. | Lewes | United States | Participant |
| Pfizer Inc | New York City | United States | Participant |
| Varian Medical Systems Inc. | Palo Alto | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI